PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Clinical Infectious Diseases1 citationsOpen Access

Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial

View Full Paper
ILIsabel Leroux‐RoelsMLMuriel LinsRSRonald Surowitz

Key Points

  • To determine the immunogenicity and safety of co-administering RSVPreF3 and PCV20 vaccines in adults aged 60 and older.
  • Conducted a randomized, non-inferiority trial
  • Participants received either the co-administered vaccines or the vaccines sequentially
  • Assessed immunogenicity and safety outcomes
  • Co-administration exhibited non-inferior immunogenicity compared to sequential administration
  • Both vaccines had an acceptable safety profile
  • Support for co-administration enhances vaccine uptake

Abstract

Co-administration of adjuvanted RSVPreF3 vaccine and PCV20 vaccine in older adults is immunologically non-inferior to their sequential administration, with an acceptable safety profile. These findings support co-administration as a strategy to enhance vaccine uptake.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Leroux‐Roels et al. (2026) studied this question.

synapsesocial.com/papers/69e471c5010ef96374d8dfcbhttps://doi.org/10.1093/cid/ciag250
Ask AI
Helpful
Bookmark
Share
View Full Paper